SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Neuland Laboratories - Quaterly Results

10 Nov 2022 Evaluate
The revenue for the September 2022 quarter is pegged at Rs. 2937.06 millions, about 13.91% up against Rs. 2578.48 millions recorded during the year-ago period.The Profit  for the quarter ended September 2022 of  Rs. 383.34  millions  grew by 88.60% from Rs. 203.26 millions.Operating Profit saw a handsome growth to 694.09 millions from 430.75 millions in the quarter ended September 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 2937.06 2578.48 13.91 5148.76 4587.35 12.24 9510.77 9369.13 1.51
Other Income 2.39 2.87 -16.72 7.51 23.43 -67.95 20.77 160.95 -87.10
PBIDT 694.09 430.75 61.14 983.99 707.33 39.11 1442.70 1625.38 -11.24
Interest 31.75 35.60 -10.81 60.33 74.03 -18.51 134.94 178.98 -24.61
PBDT 662.34 395.15 67.62 923.66 633.30 45.85 1307.76 1446.40 -9.59
Depreciation 131.72 119.82 9.93 259.70 238.10 9.07 490.36 396.78 23.58
PBT 530.62 275.33 92.72 663.96 395.20 68.01 817.40 1049.62 -22.12
TAX 147.28 72.07 104.36 182.21 105.46 72.78 182.06 246.67 -26.19
Deferred Tax 3.96 15.84 -75.00 -2.11 15.97 -113.21 -22.16 121.84 -118.19
PAT 383.34 203.26 88.60 481.75 289.74 66.27 635.34 802.95 -20.87
Equity 129.01 129.01 0.00 129.01 129.01 0.00 129.00 129.00 0.00
PBIDTM(%) 23.63 16.71 41.46 19.11 15.42 23.94 15.17 17.35 -12.56

Neuland Laboratories Share Price

17177.50 225.25 (1.33%)
12-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1807.25
Dr. Reddys Lab 1273.90
Cipla 1388.80
Zydus Lifesciences 1104.35
Lupin 2292.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: